Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder

Abstract

Objective

Lisdexamfetamine dimesylate is a stimulant prodrug with low abuse and diversion potential that is used in treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults. This current literature review article aims to examine safety and efficacy of LDX in children and adolescents for the treatment of ADHD based on currently available data.

Methods

Relevant English language articles were identified through computerized searches of the MEDLINE database (PubMed and EMBASE) and clinical trials registry up to January 2020 using the following search terms: lisdexamfetamine dimesylate, pro-drug stimulant, attention-deficit and hyperactivity disorders, ADHD, safety, efficacy, children, adolescents, Vyvanse. Forty-two articles were reviewed, 34 of which were included into this review, selected by the limit “clinical trials”. This article represents the pharmacological profile, efficacy and safety data of LDX for the treatment of ADHD in children and adolescents.

Results

The collection of studies reviewed identified that LDX was both safe and efficacious in the treatment of ADHD. The most commonly exhibited side effects were appetite suppression, weight loss, headache and insomnia. In comparison to placebo, LDX significantly improved ADHD symptoms and overall quality of life in children and adolescents. In comparison to atomoxetine, LDX showed statistically significant improvements in inattention, impulsivity, and activities of daily living. In comparison to OROS-MPH and placebo, LDX and OROS-MPH showed improvements with the CGI-I score, and ADHD-RS-IV, however, LDX was superior.

Conclusion

Patients have seen statistically significant improvements in their ADHD symptomatology in the classroom environment, health related quality of life, and their overall behavior in comparison to placebo, atomoxetine, and OROS-MPH. However, clinical judgment should be utilized when prescribing LDX due to patient specific needs and the side effect profile.

Keywords:

• Lisdexamfetamine dimesylate
• prodrug-stimulant
• attention-deficit and hyperactivity disorders
• ADHD
• safety
• efficacy
• children
• adolescents
• Vyvanse

Transparency

Declaration of funding

No funding to declare.

Declaration of financial/other relationships

The authors and peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions

JN coordinated and retrieved the computerized searches for data analysis, analyzed studies, drafted the initial manuscript, and approved the final manuscript as submitted. ED, DM, KY and KM coordinated and retrieved the computerized searches for data analysis, analyzed studies, reviewed the manuscript and approved the final manuscript as submitted. JR and MT analyzed studies, reviewed the manuscript and approved the final manuscript as submitted.

Acknowledgements

None reported.